Eli Lilly and Company And Alkermes Release: Data On AIR(R) Inhaled Insulin System Presented At American Diabetes Association Meeting

WASHINGTON, D.C., June 10 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY - News) and Alkermes, Inc. (Nasdaq: ALKS - News) today reported new study results of the companies' investigational AIR® Inhaled Insulin System(1) (AIR insulin system), including the first published analysis of the effect of chronic obstructive pulmonary disease (COPD) on inhaled insulin absorption and action; the importance to patients of simple, patient-directed training of an inhaled insulin system; and dosing flexibility with the AIR insulin system. These study findings were presented at the American Diabetes Association's (ADA) 66th Annual Scientific Sessions. The AIR insulin system is currently in Phase 3 clinical development by Lilly and Alkermes, and is being studied as an innovative treatment for type 1 and type 2 diabetes.